FDA warns of injury, death with herbal supplement kratom

November 14, 2017 by Matthew Perrone
FDA warns of injury, death with herbal supplement kratom
In this Sept. 27, 2017, file photo, kratom capsules are displayed in Albany, N.Y. Federal health authorities on Tuesday, Nov. 14, are warning about reports of injury, addiction and death with the herbal supplement that has been promoted as an alternative to opioid painkillers and other prescription drugs. (AP Photo/Mary Esch, File)

Federal health authorities are warning about reports of injury, addiction and death with a herbal supplement that has been promoted as an alternative to opioid painkillers and other prescription drugs

The supplement, kratom, made from a plant native to Southeast Asia, has gained popularity in the U.S. as a treatment for pain, anxiety and . Users have opposed efforts to regulate the plant, saying it could be a safer alternative to opioid pain pills that have caused an epidemic of abuse.

But the Food and Drug Administration said Tuesday that kratom carries similar risks, including addiction and death, and the agency is working to block shipments.

The FDA said it is aware of 36 deaths involving products made with kratom and hundreds of calls to poison control centers, which increased tenfold between 2010 and 2015. In some cases, kratom is mixed with opioids like oxycodone, the ingredient in OxyContin, according to the agency.

"The FDA must use its authority to protect the public from addictive substances like kratom, both as part of our commitment to stemming the and preventing another from taking hold," FDA Commissioner Scott Gottlieb, said in a statement .

Gottlieb said the agency has seized and destroyed shipments of kratom at international mail facilities.

Kratom remains legal under federal law although some states have banned the plant, including Alabama, Arkansas, Indiana, Tennessee and Wisconsin. It is sold in various forms, including capsules and powders.

The Drug Enforcement Administration had planned to ban the plant by adding it to a list of illegal drugs that includes marijuana, heroin and LSD. But the agency backed away from that plan last October after a flood of public complaints including a letter signed by 62 members of Congress and a protest at the White House organized by the American Kratom Association.

A spokesman for the group could not immediately provide comment Tuesday morning.

The group has said categorizing kratom as an illegal substance would stymie medical research into its potential therapeutic uses. The DEA said last October it would delay a decision until the FDA issued a recommendation.

Despite Tuesday's warning about the risks of kratom an FDA spokeswoman said the agency's scientific review is ongoing. There is no timetable for completing the review.

Explore further: DEA halts move to ban controversial herbal kratom

Related Stories

DEA halts move to ban controversial herbal kratom

October 14, 2016
(HealthDay)—Bowing to public pressure, the U.S. Drug Enforcement Administration has halted a move to ban a plant called kratom, which experts say could help battle the nation's opioid epidemic.

Researchers suggest kratom may have medical benefit as opioid alternative

November 28, 2016
A delayed U.S. Drug Enforcement Administration ban on kratom would stifle scientific understanding of the herb's active chemical components and documented pharmacologic properties if implemented, according to a special report ...

States ban kratom supplement over abuse worries

May 20, 2016
A little-known plant-based substance often sold as an herbal supplement to address chronic pain is raising alarm bells in states concerned that it could be as addictive as heroin.

DEA puts quota on production of opioid painkillers

October 6, 2016
(HealthDay)—The U.S. Drug Enforcement Administration (DEA) says it has mandated significant cuts in the production of powerful prescription opioid painkillers.

Panel calls on FDA to review safety of opioid painkillers

July 13, 2017
The U.S. Food and Drug Administration should review the safety and effectiveness of all opioids, and consider the real-world impacts the powerful painkillers have, not only on patients, but also on families, crime and the ...

CDC launches opioid campaign in hard-hit states

September 26, 2017
(HealthDay)—The U. S. Centers for Disease Control and Prevention has launched a campaign to reduce overdose deaths from prescription opioid painkillers.

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.